DE2831507A1 - (alle-z)-5,8,11,14,17-eicosapentaensaeure und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung - Google Patents

(alle-z)-5,8,11,14,17-eicosapentaensaeure und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung

Info

Publication number
DE2831507A1
DE2831507A1 DE19782831507 DE2831507A DE2831507A1 DE 2831507 A1 DE2831507 A1 DE 2831507A1 DE 19782831507 DE19782831507 DE 19782831507 DE 2831507 A DE2831507 A DE 2831507A DE 2831507 A1 DE2831507 A1 DE 2831507A1
Authority
DE
Germany
Prior art keywords
formulation according
formulation
acid
eicosapentaenoic acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19782831507
Other languages
German (de)
English (en)
Other versions
DE2831507C2 (ko
Inventor
Hans Olaf Bang
Joern Dyerberg
Salvador Enrique Moncada
John Robert Vane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2357578A external-priority patent/GB1604554A/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of DE2831507A1 publication Critical patent/DE2831507A1/de
Application granted granted Critical
Publication of DE2831507C2 publication Critical patent/DE2831507C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C15/00—Butter; Butter preparations; Making thereof
    • A23C15/12—Butter preparations
    • A23C15/126—Butter containing a minority of vegetable oils; Enrichment of butter with fatty acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE19782831507 1978-05-26 1978-07-18 (alle-z)-5,8,11,14,17-eicosapentaensaeure und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung Granted DE2831507A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2357478 1978-05-26
GB2357578A GB1604554A (en) 1978-05-26 1978-05-26 Pharmaceutical and food formulations

Publications (2)

Publication Number Publication Date
DE2831507A1 true DE2831507A1 (de) 1979-11-29
DE2831507C2 DE2831507C2 (ko) 1989-07-13

Family

ID=26256599

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19782831507 Granted DE2831507A1 (de) 1978-05-26 1978-07-18 (alle-z)-5,8,11,14,17-eicosapentaensaeure und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung

Country Status (13)

Country Link
JP (1) JPS5515444A (ko)
AU (1) AU527784B2 (ko)
CA (1) CA1151068A (ko)
CH (1) CH644267A5 (ko)
DE (1) DE2831507A1 (ko)
ES (1) ES8104983A1 (ko)
FR (1) FR2426461A1 (ko)
IE (1) IE48287B1 (ko)
IL (1) IL55227A (ko)
IT (1) IT1116505B (ko)
NL (1) NL191332C (ko)
NZ (1) NZ187908A (ko)
SE (1) SE448678B (ko)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3325130A1 (de) * 1983-06-29 1985-01-03 Pierre-Richard Nizza Dick Pharmazeutische zusammensetzung zur anwendung fuer die haut auf der basis von essentiellen fettsaeuren und diese enthaltende vorrichtung
DE3438630A1 (de) * 1983-10-24 1985-05-02 Century Laboratories, Inc., Port Washington, N.Y. Kombinierte fettsaeurezusammensetzung zur senkung des cholesterin- und triglycerid-blutspiegels
DE19503993A1 (de) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
DE10056351A1 (de) * 2000-11-14 2002-05-29 Weylandt Karsten Henrich Pharmazeutisches Präparat

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
JPS59172416A (ja) * 1983-03-18 1984-09-29 Terumo Corp 脂肪輸液
JPS60132916A (ja) * 1983-12-21 1985-07-16 Nisshin Oil Mills Ltd:The 血栓症予防食品または医薬品
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
JPH0748991B2 (ja) * 1984-08-29 1995-05-31 日本油脂株式会社 経管栄養組成物
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
NL9401743A (nl) * 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
EP3797591A1 (en) 2009-04-29 2021-03-31 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
BRPI1014405A2 (pt) 2009-04-29 2016-04-05 Amarin Corp Plc composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso
KR20120016677A (ko) 2009-06-15 2012-02-24 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
HUE053111T2 (hu) 2012-06-29 2021-06-28 Amarin Pharmaceuticals Ie Ltd Módszerek kardiovaszkuláris események veszélyének csökkentésére sztatin terápiával kezelt alanyban eikozapentaénsav-etilészter alkalmazásával
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
EP2953962A4 (en) 2013-02-06 2016-10-19 Agency Science Tech & Res METHODS OF REDUCING AGGREGATES IN PROTEIN PREPARATIONS
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
PT4056176T (pt) 2018-09-24 2024-05-27 Amarin Pharmaceuticals Ie Ltd Métodos de redução do risco de eventos cardiovasculares num indivíduo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476624A (en) * 1973-05-30 1977-06-16 Cepbepe Tranquiliser medicaments
DE2749492A1 (de) * 1976-11-04 1978-05-11 Bio Oil Res Antithrombosemittel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE319677B (ko) * 1965-03-27 1970-01-19 Sumitomo Chemical Co
FR2097036A1 (en) * 1970-07-29 1972-03-03 Sopharga Lab Lipids contg fatty acids - for treatment of atheroslerosis
JPS6257605A (ja) * 1985-09-05 1987-03-13 Kaizuka Kazutoshi 多元素鉱物からの有効成分抽出方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476624A (en) * 1973-05-30 1977-06-16 Cepbepe Tranquiliser medicaments
DE2749492A1 (de) * 1976-11-04 1978-05-11 Bio Oil Res Antithrombosemittel

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts CA Vol. 81, 1974, Nr. 612516 *
Pharmazeutische Zeitung 118, Nr.40, 04.10.1973 *
SILVER, M. J., et al., Prostaglandins 4, 1973, S. 863-875 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3325130A1 (de) * 1983-06-29 1985-01-03 Pierre-Richard Nizza Dick Pharmazeutische zusammensetzung zur anwendung fuer die haut auf der basis von essentiellen fettsaeuren und diese enthaltende vorrichtung
DE3438630A1 (de) * 1983-10-24 1985-05-02 Century Laboratories, Inc., Port Washington, N.Y. Kombinierte fettsaeurezusammensetzung zur senkung des cholesterin- und triglycerid-blutspiegels
DE19503993A1 (de) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
DE10056351A1 (de) * 2000-11-14 2002-05-29 Weylandt Karsten Henrich Pharmazeutisches Präparat

Also Published As

Publication number Publication date
NL191332C (nl) 1995-06-01
CH644267A5 (en) 1984-07-31
JPS5515444A (en) 1980-02-02
IE48287B1 (en) 1984-11-28
SE448678B (sv) 1987-03-16
IL55227A0 (en) 1978-09-29
FR2426461A1 (fr) 1979-12-21
AU3808478A (en) 1980-01-17
IL55227A (en) 1982-12-31
IT7947717A0 (it) 1979-01-19
FR2426461B1 (ko) 1983-02-11
IT1116505B (it) 1986-02-10
DE2831507C2 (ko) 1989-07-13
ES480921A0 (es) 1981-05-16
AU527784B2 (en) 1983-03-24
SE7904570L (sv) 1979-11-27
IE791023L (en) 1979-11-26
ES8104983A1 (es) 1981-05-16
NL7904144A (nl) 1979-11-28
NZ187908A (en) 1984-05-31
NL191332B (nl) 1995-01-02
CA1151068A (en) 1983-08-02

Similar Documents

Publication Publication Date Title
DE2831507C2 (ko)
DE3687347T2 (de) Schnellwirkende, intravenoese emulsionen von omega-3-fettsaeureestern.
AT398779B (de) Fettsäurezusammensetzung, verfahren zu ihrer herstellung, ihre verwendung und pharmazeutische zusammensetzung, die sie enthält
US4058594A (en) Immuno-suppressive agents
Vergroesen Dietary fat and cardiovascular disease: possible modes of action of linoleic acid
DE4133694C2 (de) Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
DE69823548T2 (de) Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis
GB2033745A (en) Fatty acid and derivatives thereof in treatment or prophylaxis of thrombo-embolic conditions
US3993775A (en) Immuno-suppressive agents
DE60029591T2 (de) Konjugierte linolensäure zur behandlung von cyclooxygenase-2 vermittelten entzündungen und schmerzen
EP0637957B1 (de) Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen
DE3438630A1 (de) Kombinierte fettsaeurezusammensetzung zur senkung des cholesterin- und triglycerid-blutspiegels
DE2749492C2 (de) Antithrombosemittel
DE69625616T3 (de) Lipidemulsionen mit optimierter hydrolyse sowie deren verwendung
DE2745695A1 (de) Pharmazeutische kombination, verfahren zu ihrer herstellung und ihre verwendung
WO2000032210A1 (de) Pharmazeutische zusammensetzung enthaltend fischöl, vitamin e und c und acetylsalicylsäure gegen arteriosklerose
GB1604554A (en) Pharmaceutical and food formulations
DE2921852A1 (de) Lipide senkendes mittel
US9808437B2 (en) Monounsaturated fatty acid compositions and use for treating atherosclerosis
JPS6257605B2 (ko)
DE3739700A1 (de) Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin
DE69736678T2 (de) Dermatologische zusammensetzungen
AT395818B (de) Auf das herz-kreislauf-system wirkende arzneimittelpraeparate und verfahren zur herstellung derselben
DE3826297A1 (de) Behandlung der hyperlipidaemie und herstellung eines arzneimittels hierfuer
DE3904674A1 (de) Verwendung einer wirkstoffkombination zur behandlung rheumatischer erkrankungen

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: BANG, HANS OLAF, LYNGBY, DK DYERBERG, JOERN, AALBO

8128 New person/name/address of the agent

Representative=s name: SCHWABE, H., DIPL.-ING. SANDMAIR, K., DIPL.-CHEM.

8127 New person/name/address of the applicant

Owner name: MOCHIDA PHARMACEUTICAL CO., LTD. NIPPON SUISAN KAI

D2 Grant after examination
8363 Opposition against the patent
8331 Complete revocation